Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-01-09
2007-01-09
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S185100, C530S300000, C530S388200
Reexamination Certificate
active
10268336
ABSTRACT:
Provided are streptolysin S (SLS) polypeptides, peptides, and variants thereof, antibodies directed thereto, and isolated nucleic acids encoding such proteins. In one embodiment, a method is provided wherein a synthetic peptide of SLS is used to elicit an immune response specific for SLS in a subject to treat or prevent a streptococcal infection. In other embodiments, antibodies that neutralize the hemolytic activity of the SLS toxin may be used as a vaccinating agent.
REFERENCES:
patent: 5229490 (1993-07-01), Tam
patent: 5580563 (1996-12-01), Tam
patent: 6063386 (2000-05-01), Dale et al.
patent: WO 99/49049 (1999-09-01), None
Dale et al, Vaccine 1996, vol. 14, No. 10.
Dale et al, Vaccine 17, 1999, 193-200.
Thomas E. Creighton, in his book, “Proteins: Structures and Molecular Properties, 1984”, (pp. 314-315).
Thomas E. Creighton, in his book “Protein Structure: A Practical Approach, 1989, pp. 184-186”.
Nosoh, Y. et al in “Protein Stability and Stabilization through Protein Engineering, 1991” (chapter 7, p. 197, second paragraph).
Dale et al., Vaccine, 1996, vol. 14, No. 10.
Thomas E. Creighton, in his book, “Proteins: Structures and Molecular Properties, 1984”.
Thomas E. Creighton, in his book “Protein Structure: A Practical Approach, 1989; pp. 184-186”.
Nosoh, Y. et al in “Protein Stability and Stabilization through Protein Engineering, 1991” (chapter 7, p. 197, second paragraph).
Dale et al, Vaccine 1996, vol. 14, No. 10.
Dale, J.B., “Group A Streptococcal Vaccines,”Infectious Disease Clinics of North America 13(1):227-243, Mar. 1999.
Dale, J.B., “Antibodies against a Synthetic Peptide of SagA Neutralize the Cytolytic Activity of Streptolysin S from Group A Streptococci,”Infection and Immunity 70(4): 2166-2170, Apr. 2002.
Alouf and Loridan, “Production, Purificatio, and Assay of Streptolysin S,”Methods in Enzymology 165: 59-64, 1988.
Beachey et al., “Type-specific protective immunity evoked by synthetic peptide ofStreptococcus pyogenesM protein,”Nature 292: 457-459, Jul. 30, 1991.
Bernheimer, A. W., “Physical Behavior of Streptolysin S,”Journal of Bacteriology 93(6):2024-2025, Jun. 1967.
Betschel et al., “Reduced Virulence of Group A Streptococcal Tn916 Mutants That Do Not Produce Streptolysin S,”Infection and Immunity 66(4): 1671-1679, Apr. 1998.
Cunningham, M.W., “Pathogenesis of Group A Streptococcal Infections,”Clinical Microbiology Reviews 13(3):470-511, Jul. 2000.
Dale et al., “Heterogeneity of Type-Specific and Cross-Reactive Antigenic Determinants within a Single M Protein of Group A Streptococci,”The Journal of Experimental Medicine 151: 1026-1038, 1980.
Dale et al., “Recombinant, octavalent group A streptococcal M protein vaccine,”Vaccine 14(10):944-948, 1996.
Dale and Beachey, “Localization of Protective Epitopes of the Amino Terminus of Type 5 Streptococcal M Protein,”Journal of Experimental Medicine 163: 1191-1202, May 1986.
Dawson et al., “Synthesis of Proteins by Native Chemical Ligation,”Science 266: 776-779, Nov. 4, 1994.
Fitzmaurice et al., “The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants,”Vaccine 14(6): 553-560, 1996.
Francis et al., “Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants,”Nature 330: 168-170, Nov. 12, 1987.
Ginsburg, I., “Is streptolysin S of group A streptococci a virulence factor?”APMIS 107: 1051-1059, 1999.
Hryniewicz and Pryjma, “Effect of Streptolysin S on Human and Mouse T and B Lymphocytes,”Infection and Immunity 16(3): 730-733, Jun. 1977.
Jackson et al., “Preparation and properties of totally synthetic immunogens,”Vaccine 18: 355-361, 2000.
Jackson et al., “Free radical induced polymerization of synthetic peptides into polymeric immunogens,”Vaccine 15(15): 1697-1705, 1997.
Kehoe et al., “Nucleotide Sequence of the Streptolysin O (SLO) Gene: Structural Homologues between SLO and Other Membrane-Damaging, Thiol-Activated Toxins,”Infection and Immunity 55: 3228-3232, Dec. 1987.
Leclerc et al., “A synthetic vaccine constructed by copolymerization of B and T cell determinants,”Eur. J. Immunol. 17:269-273, 1987.
Nizet et al., “Genetic Locus for Streptolysin S Production by Group A Streptococcus,”Infection and Immunity 68(7): 4245-4254, Jul. 2000.
O'Brien-Simpson et al., “Polymerization of Unprotected Synthetic Peptides: A View toward Synthetic Peptide Vaccines,”J. Am. Chem. Soc. 119: 1183-1188, 1997.
Ofek et al., “Oxygen-Stable Hemolysins of Group A Streptococci,”Infection and Immunity 6(4): 459-464, Oct. 1972.
Rose, K., “Facile Synthesis of Homogeneous Artificial Proteins,”J. Am. Chem. Soc. 116: 30-33, 1994.
Sahl and Bierbaum, “Lantibiotics: Biosynthesis and Biological Activities of Uniquely Modified Peptides from Gram-Positive Bacteria,”Annu. Rev. Microbiol. 52: 41-79, 1998.
Senitzer and Freimer, “Autoimmune Mechanisms in the pathogenesis of Rheumatic Fever,”Reviews of Infectious diseases 6(6): 832-839, Nov.-Dec. 1984.
Smith and Scott, “Libraries of Peptides and Proteins Displayed on Filamentous Phage,”Methods in Enzymology 217: 228-257, 1993.
Stevens, D.L., “The Flesh-Eating Bacterium: What's Next?”The Journal of Infectious Diseases 179(Suppl. 2): S366-S374, 1999.
Tam, J.P., “Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system,”Proc. Natl. Acad. Sci. USA 85: 5409-5413, Aug. 1988.
Tam and Spetzler, “Chemoselective Approaches to the Preparation of Peptide Dendrimers and Branched Artificial Proteins Using Unprotected Peptides as Building Blocks,”Biomed. Pept. Proteins Nucleic Acids 1(3): 123-132, 1995.
Theodore and Calandra, “Streptolysin S Activation by Lipoteichoic Acid,”Infection and Immunity 33: 326-328, 1981.
Wannamaker, L. W., “Streptococcal Toxins,”Reviews of Infectious Diseases 5(Suppl 4): S723-S732, Sep.-Oct. 1983.
Ford Vanessa L.
Minnifield Nita
Seed IP Law Group PLLC
University of Tennessee Research Corporation
LandOfFree
Streptococcal streptolysin S vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcal streptolysin S vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcal streptolysin S vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3751481